Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

NCT05712902 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

NCT07182682 ·Status: RECRUITING ·Phase: PHASE3

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

NCT05863819 ·Status: WITHDRAWN

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

NCT06864624 ·Status: RECRUITING ·Phase: PHASE2

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC

NCT06348927 ·Status: RECRUITING ·Phase: PHASE2

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

NCT05536505 ·Status: RECRUITING ·Phase: PHASE2

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

NCT06671379 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728 ·Status: RECRUITING ·Phase: PHASE2

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NCT06361927 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

NCT03856697 ·Status: UNKNOWN ·Phase: PHASE3

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

NCT04785742 ·Status: UNKNOWN ·Phase: PHASE2

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

NCT06694129 ·Status: NOT_YET_RECRUITING

Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification

NCT03888092 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

NCT04207775 ·Status: COMPLETED

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

NCT02618590 ·Status: UNKNOWN

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

NCT06812871 ·Status: COMPLETED ·Phase: PHASE2

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

NCT01996098 ·Status: TERMINATED ·Phase: PHASE3